Corcept Therapeutics Inc (CORT) stock
CORTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/30349% above fair value
$72.94−0.77 (-1.04%)
Close on Nov 13, 2026Market cap $7.88BP/E 173.7Yield –
Corcept Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Corcept Therapeutics's EV/EBITDA was 99.2× on Apr 30, 2026, against 52.1× a year earlier. Over the last 5 years it ranged from 15.6× to 136.2×, with a median of 23.8×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 99.2× | +43.1 |
| 2025 | Dec 31, 2025 | 56.1× | +19.8 |
| 2024 | Dec 31, 2024 | 36.3× | +3.0 |
| 2023 | Dec 29, 2023 | 33.3× | +17.8 |
| 2022 | Dec 30, 2022 | 15.6× | −2.5 |
| 2021 | Dec 31, 2021 | 18.1× | −2.9 |
| 2020 | Dec 31, 2020 | 20.9× | +8.6 |
| 2019 | Dec 31, 2019 | 12.3× | −5.1 |
| 2018 | Dec 31, 2018 | 17.4× | −37.4 |
| 2017 | Dec 29, 2017 | 54.8× | −57.3 |
| 2016 | Dec 30, 2016 | 112.1× | – |
See a number that looks wrong?